Vertex Pharmaceuticals VRTX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Product revenues, net by Product | ||||||
| ALYFTREK | $1.21B+44.2% | $837.8M+83.0% | $457.7M+117% | $210.7M+291% | $53.9M— | |
| CASGEVY | $144.5M+24.8% | $115.8M+66.6% | $69.5M+27.3% | $54.6M+126% | $24.2M+142% | |
| JOURNAVX | $87.3M+46.5% | $59.6M+81.2% | $32.9M+147% | $13.3M+923% | $1.3M— | |
| Other CF product revenues | $785.2M-2.4% | $804.6M+6.1% | $758.4M-1.4% | $769.5M+5.4% | $729.8M-6.6% | |
| TRIKAFTA/KAFTRIO | $10.13B-1.8% | $10.31B-1.4% | $10.46B+0.7% | $10.39B+1.0% | $10.29B+0.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Vertex Pharmaceuticals break its business down?
- Vertex Pharmaceuticals (VRTX) reports product revenues, net by product across 5 parts — ALYFTREK, CASGEVY, JOURNAVX, Other CF product revenues and TRIKAFTA/KAFTRIO. Each is extracted from the segment footnotes and tracked over time.
- Where does Vertex Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Vertex Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
